Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity
November 17, 2020
Webinar
NERA Economic Consulting
As part of NERA Economic Consulting online education series, Finnegan attorneys Amy Fulton and Ryan O’Quinn will discuss reasons to list patents in the FDA Orange Book, recent congressional activity in pharma patents, FDA policy changes, and recent trends in patent issuance and patent exclusivity. For more information, or to register, please see NERA’s website.
Tags
505(b)(2) application, drugs, Food and Drug Administration (FDA), generic drug, Orange Book, infringement, patent exclusivity, United States Patent and Trademark Office (USPTO)
Related Practices
Related Industries
Related Professionals
- Amy L. Fulton
- Associate
- Washington, DC
- +1 202 408 4438
